High Prevalence of Cancer to Boost Demand for Contrast Media/Contrast Agent

 


A contrast agent (also called a contrast medium) is an electrically charged material used in medical imaging to enhance the contrast of medical vessels or other tissues in the body. Contrast media/contrast agent either absorbs or changes ultrasound or electromagnetism, which is fundamentally different from radiopharms, which themselves emit electromagnetic radiation. This difference enables contrast agents to be applied to various body tissues with much higher strengths than their non-comp contrast counterparts.

The most common contrast media/contrast agent used in medical imaging are CT contrast agents and MRI contrast agents. However, due to their non-magnetic nature, these medical imaging products are not able to be used on organ tissues, such as kidneys, hearts and lungs. Some manufacturers have now started manufacturing non-magnetic, biologically engineered CT and MRI contrast agents called mri-notherapy (mammography, radiofrequency ablation, and ultrasound contrast agents).

High prevalence of cancer is expected to boost demand for contrast media. In the U.S., non-magnetic, biologically engineered CT and MRI contrast agents are now being used more frequently to treat patients with benign tumors of all types. Mri-notherapy is used for benign cancers of the breast (breast cancer), abdomen (belly fat), neck, head, joint (arthritis) and spine. Patients with melanoma, anemia, inoperable basilar artery disease, and multiple myeloma are also often treated with mri-notherapy. The therapy has a high success rate for benign tumors and very low incidence of mortality, espeacially in patients undergoing surgery. Moreover, recently, in November 2020, the U.S. FDA approved GE Healthcare’s macrocyclic gadolinium-based MRI contrast agent, Clariscan (gadoterate meglumine), in pre-filled syringes.

For targeted nanoparticles, CT imaging modalities such as ultrasound and laser ablation have been used. Ultrasound is useful in early detection of cancerous cells and its use in conjunction with laser ablation is very effective in removing tumors. Both ultrasound and laser ablation have good safety records. Chemotherapy or radiotherapy using medication to kill malignant cells is not a traditional contrast agent and therefore has not been reported to cause adverse side effects.

Contrast agent delivery systems have evolved over the years to deliver medications, intravenously, intramuscularly, or subcutaneously. One of the oldest and most common systems is computed tomography (CT) imaging devices. CT images are highly detailed and able to show much detail of internal structures such as organs and tissue. Other diagnostic imaging devices include magnetic resonance imaging (MRI), radionuclide imaging (RMI), and ultrasound or laser ablation systems. The use of contrast agents in medical imaging has increased greatly in clinical practice over the past few decades because contrast agents increase contrast sensitivity and reduce the need for surgery.

Ultrasound imaging, in contrast to radiology, requires no contrast agent except for X-rays. Ultrasound imaging uses sound waves to create images from within cavities. This type of medical imaging uses sound waves rather than radiation to produce images; therefore, ultrasound imaging is less harmful than radiology imaging. This is because ultrasound imaging is non-invasive, painless, and can be used in a wide range of situations.

 

However, there are times when it is necessary to use contrast agents such as intravenous or oral contrast agents because imaging techniques cannot reveal the exact image with just ultrasound alone. For instance, CT scans can reveal internal bleeding or the presence of tumors. If these agents were to be ingested by the patient, it would change the chemical composition of their blood, causing a serious side effect. This is why it is important to use a good, reliable contrast agent such as cteprulose butyric acid (CTFA), which can be used to neutralize any potentially dangerous metals in the patient's body. It is also important that the patients who will undergo CT scanning and other imaging procedures know what the alternatives are for using contrast agents during the procedure.

While it is true that contrast agents are useful for many medical imaging methods, it is also true that using them in all cases is not necessarily safe. Patients who undergo anesthesia and are given intravenous fluids that contain gold particles are most at risk of contracting gastrointestinal side effects. These are known as "sensitivity" and have the potential to cause vomiting, diarrhea and cramping. Gold particles are also known to cause abnormalities in the kidneys, and in rare cases can cause life-threatening heart attacks. For these reasons, CTFA is usually the preferred contrast agent in patients undergoing any sort of intravenous fluid therapy or imaging methods.

Comments